NCT03136068View on ClinicalTrials.gov

Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation

PHASE4CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

February 23, 2017

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Abortion
Interventions
DRUG

Digoxin

Trans-abdominal injection

DRUG

Placebo

Trans-abdominal injection

Trial Locations (3)

90806

FPA Women's Health, Long Beach

94110

SFGH Women's Options Center, San Francisco

97210

Lovejoy Surgicenter, Portland

Sponsors

Collaborators (1)

FPA Women's Health
All Listed Sponsors
collaborator

FPA Women's Health

UNKNOWN

collaborator

Society of Family Planning

OTHER

collaborator

Oregon Health and Science University

OTHER

lead

University of California, San Francisco

OTHER

NCT03136068 - Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation | Biotech Hunter | Biotech Hunter